1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Stage IIB Breast Cancer
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Stage IIB Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LENVATINIB University Medical Center Groningen | Phase 4 | BBB |
Decitabine Virginia Commonwealth University | Phase 2 | B |
18f-flt University of Washington | Phase 2 | B |
FALLYPRIDE National Cancer Institute (NCI) | Phase 2 | B |
Tislelizumab National Cancer Institute (NCI) | Phase 2 | CCC |
Pumvc3-Igfbp2-Her2-Igf1R Plasmid Dna Vaccine University of Washington | Phase 1 | CC |
Same molecule, other indications
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →